Product information
From Health Canada
No match found
No other product was found with the same active ingredient group.
The product monograph is developed by a drug sponsor according to guidelines published by Health Canada that provide direction on the content and format. The veterinary labelling is developed by the drug sponsor according to the Food and Drug Regulations. While Health Canada reviews the product monograph or the veterinary labelling as part of the drug review process, it remains the responsibility of the drug sponsor to ensure that the product monograph or the veterinary labelling is complete and accurate.
Current status:
Cancelled Post Market
Current status date:
2015-01-28
Original market date: See footnote 1
1995-12-31
Product name:
MAXIPIME FOR INJECTION -PWS IV IM 1G
DIN:
02163632
Product Monograph/Veterinary Labelling:
Date:
2008-09-23
Product monograph/Veterinary Labelling (PDF version ~ 175K)
Company:
BRISTOL-MYERS SQUIBB CANADA
2344 Boul. Alfred-Nobel, Suite 300
St-Laurent
Quebec
Canada
H4S 0A4
Class:
Human
Dosage form(s):
Powder For Solution
Route(s) of administration:
Intravenous , Intramuscular
Number of active ingredient(s):
1
Schedule(s):
Prescription
American Hospital Formulary Service (AHFS): See footnote 3
08:12.06.16
Anatomical Therapeutic Chemical (ATC): See footnote 4
J01DE01 CEFEPIME
Active ingredient group (AIG) number:See footnote5
0150504001
| Active ingredient(s) See footnote8 | Strength |
|---|---|
| CEFEPIME (CEFEPIME HYDROCHLORIDE) | 1 G / VIAL |